2019 American Transplant Congress
Letermovir for CMV Treatment in Solid Organ Transplant
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Letermovir (LET), a novel anti-CMV agent, was recently approved for CMV prophylaxis in stem cell transplant recipients and is currently under investigation as a…2019 American Transplant Congress
Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients
*Purpose: In kidney transplant recipients (KTR), cytomegalovirus (CMV) is a common viral infection associated with significant morbidity and mortality. In the absence of prophylaxis, CMV…2019 American Transplant Congress
Undernutrition and Leptin Deficiency Modulates T Cell Immunity in Transplantation
1Pediatrics, Duke University, Durham, NC, 2Surgery, Duke University, Durham, NC
*Purpose: We have previously shown an association between undernutrition and the development of viremia in transplanted children. While undernutrition is associated with impaired T cell…2019 American Transplant Congress
De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients
*Purpose: Letermovir, cytomegalovirus (CMV) DNA-terminase complex (UL51, UL56, and UL89) inhibitor, revealed the efficient prophylactic effect against CMV infection including disease and DNAemia with low-grade…2019 American Transplant Congress
No Indication of Increased CMV Infection in Kidney Transplant Recipients without Pharmacological Prophylaxis Receiving a Single 3mg/kg Dose of Rabbit Anti-Thymocyte Globulin (ATG) Instead of No-Induction
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Induction therapy with rabbit anti-thymocyte globulin (ATG) in patients at low immunological risk remains controversial, given increased risk of cytomegalovirus (CMV) infection*Methods: To investigate…2019 American Transplant Congress
A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers and Entering a Phase 2 Trial in Kidney Transplant Recipients
*Purpose: Cytomegalovirus (CMV) is a significant pathogen in pregnancy and immunocompromised patients. Antiviral prophylaxis is limited by toxicities, recurrent infection, and resistance. A safe and…2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2019 American Transplant Congress
Murine Cytomegalovirus Infection Down-Regulates Receptor Tyrosine Kinase MerTK on Macrophages to Abrogate Allograft Tolerance
*Purpose: Cytomegalovirus (CMV) is one of the most common pathogens infecting solid organ transplant recipients. We recently showed that (1) CMV infection impairs the induction…2019 American Transplant Congress
Donor Graft CMV Serostatus Influences the Development of Arterial and Venous Vascular Events in Seronegative Recipients after Organ Transplantation
University of Alberta, Edmonton, AB, Canada
*Purpose: Cytomegalovirus (CMV) is the most common opportunistic pathogen following solid organ transplantation (SOT) and is a major cause of morbidity and mortality. CMV infection…2019 American Transplant Congress
Predicting Risk of Cytomegalovirus with Viral-Antigen-Specific CD154+ T-cells after Liver or Intestine Transplantation
Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA
*Purpose: Cytomegalovirus (CMV)-specific T-cells express IFNγ, measure cell-mediated immunity to CMV and can guide the timing and duration of antiviral therapy. CMV-specific T-cells also co-express…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 33
- Next Page »